Sam's News — health — 2026-08-30¶
Health¶
7.5 CAR T-cell cancer therapy achieves remission in severe rheumatoid arthritis¶
CAR T-cell therapy, borrowed from cancer treatment, dramatically reduced disease activity in six patients with severe rheumatoid arthritis resistant to other drugs, with three achieving medication-free remission. The therapy genetically modifies immune cells to eliminate disease-driving B cells even in hard-to-reach locations like bone marrow and joint tissue.
- Six patients with treatment-refractory rheumatoid arthritis
- Three achieved medication-free remission by end of observation period
- Therapy targets and eliminates B cells that produce harmful antibodies
- CAR T cells cleared inflammatory foci in deep tissue locations
- Study published Nature Medicine, August 2026
- Conducted by Charité - Universitätsmedizin Berlin researchers
Sources: ScienceDaily AI Web Searched, ScienceDaily — Health RSS
6.5 Researchers develop bioavailable spirulina with natural vitamin B12¶
Researchers produced spirulina containing biologically active vitamin B12 at beef-comparable levels by controlling light conditions during cultivation.
Sources: ScienceDaily RSS, ScienceDaily — Health RSS, ScienceDaily — Nutrition RSS
6.5 Omega-3 and aspirin match antibiotic efficacy for severe gum disease¶
A year-long study found that omega-3 and low-dose aspirin matched antibiotics in treating severe gum disease, with both approaches achieving treatment goals in about 58% of patients.
Sources: ScienceDaily — Health RSS
6 HEPA air purifiers boost cognitive performance after one month¶
Adults aged 40+ showed 12% faster executive function performance after using HEPA air purifiers for one month, suggesting cleaner air protects brain health.
Sources: ScienceDaily RSS, ScienceDaily — Health RSS
Healthcare¶
7 FDA approves Mimrylo for rare blood cancer polycythemia vera¶
The FDA approved Mimrylo (rusfertide), a weekly injection for polycythemia vera, a chronic blood cancer marked by excessive red blood cell production that increases risk of heart attacks, strokes, and clots. The treatment was developed by Protagonist Therapeutics and is sold by Takeda.
- Mimrylo is a weekly injection
- Developed by Protagonist Therapeutics, sold by Takeda
- Treats polycythemia vera, a chronic blood cancer
- Approved August 30, 2026
Sources: STAT News AI Web Searched
6 Alnylam defends heart disease drug portfolio after AstraZeneca trial failure¶
Alnylam is mounting a defense of its heart disease medications after AstraZeneca's Wainua drug trial failure.
Sources: STAT News RSS